Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus TRIMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus TRIMPEX.
FORBAXIN vs TRIMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
IV: 500 mg every 12 hours, infused over 30 minutes.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Renal (60-70% unchanged), biliary/fecal (20-30%)
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Category C
Category C
Antibiotic
Antibiotic